Roche acquires GNMK for $24.05 cash—a 30% premium to Friday’s close, and a 43% premium to GNMK’s “unaffected” share price on 2/10/21 (before leaks of the buyout discussions): https://www.globenewswire.com/news-release/2021/03/15/2192442/0/en/Roche-signs-definitive-merger-agreement-with-GenMark-Diagnostics-Inc-to-access-novel-technology-to-test-for-broad-range-of-pathogens-with-one-patient-sample.html The nominal deal price is $1.8B.